Parkinson’s Treatment Report

www.ParkinsonsTreatmentReport.com

Clinical Trials

A Clinical Study of NLY01 in Patient’s With Early Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT04154072?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=10%2F23%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Clinical Study of NLY01 in Patient’s With Early Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: NLY01;   Drug: Vehicle
Sponsor:   Neuraly, Inc.
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT04154072

FIRST POSTED:
Wed, 06 Nov 2019 12:00:00 EST

LAST UPDATE POSTED:
11/06/19 08:26AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04154072?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=10%2F23%2F2019&lupd_d=14&sort=nwst

Microbiota Intervention to Change the Response of Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03575195?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=07%2F31%2F2020&lupd_d=14&sort=nwst

STUDY TITLE:
Microbiota Intervention to Change the Response of Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: Rifaximin;   Other: Placebo
Sponsors:   University of California, San Francisco;   Nova Southeastern University;   Gateway Institute for Brain Research
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03575195

FIRST POSTED:
Mon, 02 Jul 2018 12:00:00 EDT

LAST UPDATE POSTED:
08/14/20 07:39AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03575195?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=07%2F31%2F2020&lupd_d=14&sort=nwst

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03976349?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F23%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson’s Disease
Interventions:   Drug: BIIB094;   Drug: Placebo
Sponsors:   Biogen;   Ionis Pharmaceuticals, Inc.
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03976349

FIRST POSTED:
Thu, 06 Jun 2019 12:00:00 EDT

LAST UPDATE POSTED:
06/06/19 07:37AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03976349?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F23%2F2019&lupd_d=14&sort=nwst

Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03318523?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F15%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson’s Disease
Interventions:   Drug: Placebo;   Drug: BIIB054
Sponsor:   Biogen
Active, not recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03318523

FIRST POSTED:
Tue, 24 Oct 2017 12:00:00 EDT

LAST UPDATE POSTED:
05/29/19 07:29AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03318523?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F15%2F2019&lupd_d=14&sort=nwst

Simvastatin as a Neuroprotective Treatment for Moderate Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT02787590?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F18%2F2020&lupd_d=14&sort=nwst

STUDY TITLE:
Simvastatin as a Neuroprotective Treatment for Moderate Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: Simvastatin;   Drug: Matched Placebo (for Simvastatin)
Sponsors:   University Hospital Plymouth NHS Trust;   University of Plymouth
Active, not recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT02787590

FIRST POSTED:
Wed, 01 Jun 2016 12:00:00 EDT

LAST UPDATE POSTED:
06/01/20 07:10AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT02787590?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F18%2F2020&lupd_d=14&sort=nwst

TSPO-PET for Neuroinflammation in Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03457493?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=04%2F13%2F2020&lupd_d=14&sort=nwst

STUDY TITLE:
TSPO-PET for Neuroinflammation in Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Intervention:   Drug: DPA-714-PET/MRI
Sponsor:   University of Alabama at Birmingham
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03457493

FIRST POSTED:
Wed, 07 Mar 2018 12:00:00 EST

LAST UPDATE POSTED:
04/27/20 09:21AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03457493?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=04%2F13%2F2020&lupd_d=14&sort=nwst

A Phase 3 Study With P2B001 in Subjects With Early Parkinson’s

https://clinicaltrials.gov/ct2/show/NCT03329508?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=08%2F15%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Phase 3 Study With P2B001 in Subjects With Early Parkinson’s

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: P2B001;   Drug: Rasagiline;   Drug: Pramipexole;   Drug: Pramipexole ER
Sponsor:   Pharma Two B Ltd.
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03329508

FIRST POSTED:
Mon, 06 Nov 2017 12:00:00 EST

LAST UPDATE POSTED:
08/29/19 10:25AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03329508?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=08%2F15%2F2019&lupd_d=14&sort=nwst

Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT04287543?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=02%2F13%2F2020&lupd_d=14&sort=nwst

STUDY TITLE:
Melatonin on Clock Genes in Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: Melatonin;   Drug: Placebos
Sponsor:   Instituto Mexicano del Seguro Social
Enrolling by invitation

CLINICALTRIALS.GOV IDENTIFIER:
NCT04287543

FIRST POSTED:
Thu, 27 Feb 2020 12:00:00 EST

LAST UPDATE POSTED:
02/27/20 09:09AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04287543?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=02%2F13%2F2020&lupd_d=14&sort=nwst

Brain Bioenergetics in Parkinson’s Disease and Response to Repeated Oral UDCA Treatment

https://clinicaltrials.gov/ct2/show/NCT02967250?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=10%2F18%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Brain Bioenergetics in Parkinson’s Disease and Response to Repeated Oral UDCA Treatment

DESCRIPTION:
Condition:   Parkinson Disease
Intervention:   Drug: ursodeoxycholic acid
Sponsor:   University of Minnesota
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT02967250

FIRST POSTED:
Fri, 18 Nov 2016 12:00:00 EST

LAST UPDATE POSTED:
11/01/19 08:39AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT02967250?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=10%2F18%2F2019&lupd_d=14&sort=nwst

A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment Associated With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT04148391?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=10%2F18%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Evaluate NYX-458 in Subjects With MCI-PD

DESCRIPTION:
Conditions:   Parkinson’s Disease;   Mild Cognitive Impairment
Interventions:   Drug: Placebo Oral Capsule;   Drug: NYX-458
Sponsors:   Aptinyx;   CogState Ltd.;   Worldwide Clinical Trials
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT04148391

FIRST POSTED:
Fri, 01 Nov 2019 12:00:00 EDT

LAST UPDATE POSTED:
11/01/19 07:39AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04148391?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=10%2F18%2F2019&lupd_d=14&sort=nwst

Transplantation of Neural Stem Cell-Derived Neurons for Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03309514?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=09%2F12%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Transplantation of Neural Stem Cell-Derived Neurons for Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson’s Disease
Intervention:   Biological: Intracerebral microinjections
Sponsor:   NeuroGeneration
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03309514

FIRST POSTED:
Fri, 13 Oct 2017 12:00:00 EDT

LAST UPDATE POSTED:
09/26/19 07:45AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03309514?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=09%2F12%2F2019&lupd_d=14&sort=nwst

Study to Evaluate APL-130277 in Subjects With Parkinson’s Disease Complicated by Motor Fluctuations

https://clinicaltrials.gov/ct2/show/NCT03391882?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F01%2F2019&lupd_d=14&sort=nwst

Study to Evaluate APL-130277 in Subjects With Parkinson’s Disease Complicated by Motor Fluctuations

Study
STUDY TITLE:
A Study of an Investigational Drug to See How it Affects the People With Parkinson’s Disease Complicated by Motor Fluctuations (“OFF” Episodes) Compared to an Approved Drug Used to Treat People With Parkinson’s Disease Complicated by Motor Fluctuations (“OFF” Episodes)

DESCRIPTION:
Condition:   Motor OFF Episodes Associated With Parkinson’s Disease
Interventions:   Drug: APL-130277;   Drug: subcutaneous apomorphine
Sponsor:   Sunovion
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03391882

FIRST POSTED:
Fri, 05 Jan 2018 12:00:00 EST

LAST UPDATE POSTED:
05/15/19 07:32AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03391882?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F01%2F2019&lupd_d=14&sort=nwst

Extension Study of Ampreloxetine (TD-9855) for Treating snOH in Subjects With Primary Autonomic Failure

https://clinicaltrials.gov/ct2/show/NCT04095793?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=09%2F05%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Extension Study of Ampreloxetine (TD-9855) for Treating snOH in Subjects With Primary Autonomic Failure

DESCRIPTION:
Condition:   Symptomatic Neurogenic Orthostatic Hypotension
Intervention:   Drug: ampreloxetine
Sponsor:   Theravance Biopharma
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT04095793

FIRST POSTED:
Thu, 19 Sep 2019 12:00:00 EDT

LAST UPDATE POSTED:
09/19/19 08:06AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04095793?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=09%2F05%2F2019&lupd_d=14&sort=nwst

Study to Evaluate DNL151 in Subjects With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT04056689?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=07%2F31%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Study to Evaluate DNL151 in Subjects With Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: DNL151 low dose;   Drug: DNL151 high dose;   Drug: Placebo
Sponsor:   Denali Therapeutics Inc.
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT04056689

FIRST POSTED:
Wed, 14 Aug 2019 12:00:00 EDT

LAST UPDATE POSTED:
08/14/19 07:51AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04056689?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=07%2F31%2F2019&lupd_d=14&sort=nwst

A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson’s Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214

https://clinicaltrials.gov/ct2/show/NCT02579473?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=09%2F04%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson’s Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214

DESCRIPTION:
Condition:   Parkinson’s Disease
Intervention:   Drug: SER-214
Sponsor:   Serina Therapeutics
Active, not recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT02579473

FIRST POSTED:
Mon, 19 Oct 2015 12:00:00 EDT

LAST UPDATE POSTED:
09/18/19 07:46AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT02579473?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=09%2F04%2F2019&lupd_d=14&sort=nwst

Open-label Investigation of the Safety and Clinical Effects of NTCELL in Patients With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT01734733?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=09%2F02%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Open-label Investigation of the Safety and Clinical Effects of NTCELL in Patients With Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson’s Disease
Intervention:   Other: NTCELL
Sponsor:   Living Cell Technologies
Active, not recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT01734733

FIRST POSTED:
Wed, 28 Nov 2012 12:00:00 EST

LAST UPDATE POSTED:
09/16/19 07:45AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT01734733?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=09%2F02%2F2019&lupd_d=14&sort=nwst

Study to Investigate the Effect of IPT803 Adjunct Treatment in Patients With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03407378?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=08%2F05%2F2019&lupd_d=14&sort=nwst

A Proof of Concept Study to Investigate the Effect of IPT803 Adjunct Treatment in Patients With Parkinson’s Disease

STUDY TITLE:
A Study to Investigate a New Treatment in Patients With Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: IPT803;   Genetic: Optional pharmacogenetic assessment;   Other: Questionnaires;   Other: Optional Blood-Oxygen-level Dependent functionalMRI;   Other: Motor Assessments before taking regular PD treatment;   Other: Motor Assessments on regular PD treatment
Sponsor:   Tools4Patient
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03407378

FIRST POSTED:
Tue, 23 Jan 2018 12:00:00 EST

LAST UPDATE POSTED:
08/19/19 10:02AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03407378?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=08%2F05%2F2019&lupd_d=14&sort=nwst

Study of UB-312 in Healthy Participants and Parkinson’s Disease Patients

https://clinicaltrials.gov/ct2/show/NCT04075318?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=08%2F16%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Study of UB-312 in Healthy Participants and Parkinson’s Disease Patients

DESCRIPTION:
Conditions:   Parkinson Disease;   Parkinsonism
Interventions:   Biological: UB-312;   Biological: Placebo
Sponsors:   United Neuroscience Ltd.;   Centre for Human Drug Research, Netherlands;   Worldwide Clinical Trials
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT04075318

FIRST POSTED:
Fri, 30 Aug 2019 12:00:00 EDT

LAST UPDATE POSTED:
08/30/19 09:00AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04075318?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=08%2F16%2F2019&lupd_d=14&sort=nwst

Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03720418?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=08%2F16%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: OXB-102;   Other: Imitation Surgical Procedure (ISP)
Sponsors:   Axovant Sciences Ltd.;   Oxford BioMedica
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03720418

FIRST POSTED:
Thu, 25 Oct 2018 12:00:00 EDT

LAST UPDATE POSTED:
08/30/19 09:00AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03720418?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=08%2F16%2F2019&lupd_d=14&sort=nwst

SRC Inhibition as a Potential Target for Parkinson’s Disease Psychosis

https://clinicaltrials.gov/ct2/show/NCT03661125?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=07%2F30%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
SRC Inhibition as a Potential Target for Parkinson’s Disease Psychosis

DESCRIPTION:
Condition:   Parkinson Disease Psychosis
Interventions:   Drug: Saracatinib;   Drug: Placebo Oral Tablet
Sponsors:   King’s College London;   AstraZeneca;   King’s College Hospital NHS Trust
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03661125

FIRST POSTED:
Fri, 07 Sep 2018 12:00:00 EDT

LAST UPDATE POSTED:
08/13/19 06:58AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03661125?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=07%2F30%2F2019&lupd_d=14&sort=nwst

Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03295786?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=06%2F21%2F2019&lupd_d=14&sort=nwst

Phase 1-2, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Via an Investigational Drug Delivery System to Patients With Parkinson’s Disease

STUDY TITLE:
Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson’s Disease

DESCRIPTION:
Conditions:   Parkinson Disease;   Movement Disorders;   Neurodegenerative Diseases;   Nervous System Diseases;   Brain Diseases
Interventions:   Drug: Cerebral Dopamine Neurotrophic Factor;   Device: Renishaw Drug Delivery System
Sponsors:   Herantis Pharma Plc.;   Renishaw plc.
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03295786

FIRST POSTED:
Thu, 28 Sep 2017 12:00:00 EDT

LAST UPDATE POSTED:
07/05/19 07:10AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03295786?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=06%2F21%2F2019&lupd_d=14&sort=nwst

A Clinical Trial Investigating the Efficacy, Safety and Tolerability of ND0612 Infusion in Subjects With Parkinson’s Disease Experiencing Motor Fluctuations

https://clinicaltrials.gov/ct2/show/NCT04006210?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=06%2F21%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Clinical Trial Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson’s Disease Experiencing Motor Fluctuations (BouNDless).

DESCRIPTION:
Condition:   Parkinson’s Disease
Interventions:   Combination Product: ND0612 Solution for SC infusion;   Combination Product: Placebo for SC infusion;   Drug: Carbidopa and Levodopa 25mg/100mg;   Drug: Placebo for Carbidopa and Levodopa 25mg/100mg
Sponsor:   NeuroDerm Ltd.
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT04006210

FIRST POSTED:
Wed, 03 Jul 2019 12:00:00 EDT

LAST UPDATE POSTED:
07/05/19 07:10AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04006210?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=06%2F21%2F2019&lupd_d=14&sort=nwst

Dose Escalation Study of Cu(II)ATSM in Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03204929?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=06%2F11%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Dose Escalation Study of Cu(II)ATSM in Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Intervention:   Drug: Cu(II)ATSM
Sponsor:   Collaborative Medicinal Development Pty Limited
Active, not recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03204929

FIRST POSTED:
Sun, 02 Jul 2017 12:00:00 EDT

LAST UPDATE POSTED:
06/25/19 06:51AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03204929?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=06%2F11%2F2019&lupd_d=14&sort=nwst

Trial of Ursodeoxycholic Acid (UDCA) for Parkinson’s Disease: The “UP” Study

https://clinicaltrials.gov/ct2/show/NCT03840005?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F28%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Trial of Ursodeoxycholic Acid (UDCA) for Parkinson’s Disease: The “UP” Study

DESCRIPTION:
Condition:   Parkinson’s Disease
Intervention:   Drug: Ursonorm
Sponsors:   Sheffield Teaching Hospitals NHS Foundation Trust;   JP Moulton Charitable Foundation;   PRO.MED.CS Praha a.s.;   Clinical Trials Research Unit, University of Sheffield
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03840005

FIRST POSTED:
Fri, 15 Feb 2019 12:00:00 EST

LAST UPDATE POSTED:
06/11/19 06:55AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03840005?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F28%2F2019&lupd_d=14&sort=nwst

Chronic Effects of DBS in Parkinson’s Disease and Dystonia

https://clinicaltrials.gov/ct2/show/NCT01934296?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F22%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Chronic Effects of DBS in Parkinson’s Disease and Dystonia

DESCRIPTION:
Conditions:   Parkinson’s Disease;   Isolated Dystonia
Intervention:   Device: Activa PC+S
Sponsors:   University of California, San Francisco;   Medtronic
Active, not recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT01934296

FIRST POSTED:
Wed, 04 Sep 2013 12:00:00 EDT

LAST UPDATE POSTED:
06/05/19 07:44AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT01934296?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F22%2F2019&lupd_d=14&sort=nwst

BTRX-246040 Study in Subjects With Parkinson’s Disease With Motor Fluctuations [Completed]

https://clinicaltrials.gov/ct2/show/NCT03608371?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F22%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
BTRX-246040 Study in Subjects With Parkinson’s Disease With Motor Fluctuations

DESCRIPTION:
Conditions:   Parkinson Disease;   Motor Disorder
Interventions:   Drug: BTRX-246040;   Drug: Placebo
Sponsor:   BlackThorn Therapeutics, Inc.
Completed

CLINICALTRIALS.GOV IDENTIFIER:
NCT03608371

FIRST POSTED:
Tue, 31 Jul 2018 12:00:00 EDT

LAST UPDATE POSTED:
06/05/19 07:44AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03608371?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F22%2F2019&lupd_d=14&sort=nwst

Study to Evaluate DNL201 in Subjects With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03710707?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F22%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Study to Evaluate DNL201 in Subjects With Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: DNL201 low dose;   Drug: DNL201 high dose;   Drug: Placebo
Sponsor:   Denali Therapeutics Inc.
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03710707

FIRST POSTED:
Thu, 18 Oct 2018 12:00:00 EDT

LAST UPDATE POSTED:
06/05/19 07:44AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03710707?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F22%2F2019&lupd_d=14&sort=nwst

Clinical Trial to Evaluate the Safety and Tolerability of Molecular Hydrogen in Patients With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03971617?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F20%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: Hydrogen;   Drug: Placebo oral tablet
Sponsor:   Stony Brook University
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03971617

FIRST POSTED:
Mon, 03 Jun 2019 12:00:00 EDT

LAST UPDATE POSTED:
06/03/19 07:42AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03971617?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F20%2F2019&lupd_d=14&sort=nwst

Effects of Lingzhi (Ganoderma) on Disease Progression in Patients With Untreated Early Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03594656?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F15%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Effects of Lingzhi on Disease Progression in Patients With Untreated Early Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: Ganoderma;   Drug: Placebos
Sponsor:   Xuanwu Hospital, Beijing
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03594656

FIRST POSTED:
Fri, 20 Jul 2018 12:00:00 EDT

LAST UPDATE POSTED:
05/29/19 07:29AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03594656?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F15%2F2019&lupd_d=14&sort=nwst

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson’s Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

https://clinicaltrials.gov/ct2/show/NCT02906020?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F08%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson’s Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

DESCRIPTION:
Condition:   Parkinson’s Disease
Interventions:   Drug: GZ/SAR402671;   Drug: Placebo
Sponsor:   Genzyme, a Sanofi Company
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT02906020

FIRST POSTED:
Mon, 19 Sep 2016 12:00:00 EDT

LAST UPDATE POSTED:
05/22/19 07:42AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT02906020?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F08%2F2019&lupd_d=14&sort=nwst

A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson’s Disease and Cognitive Impairment

https://clinicaltrials.gov/ct2/show/NCT03713957?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F08%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson’s Disease and Cognitive Impairment

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: GRF6021;   Other: Placebo
Sponsors:   Alkahest, Inc.;   Michael J. Fox Foundation for Parkinson’s Research
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03713957

FIRST POSTED:
Mon, 22 Oct 2018 12:00:00 EDT

LAST UPDATE POSTED:
05/22/19 07:42AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03713957?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F08%2F2019&lupd_d=14&sort=nwst

Modulation of Gut Microbiota by Rifaximin in PD Patients

https://clinicaltrials.gov/ct2/show/NCT03958708?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F08%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Modulation of Gut Microbiota by Rifaximin in PD Patients

DESCRIPTION:
Conditions:   Parkinson Disease;   Inflammation
Intervention:   Drug: Rifaximin 550 MG
Sponsor:   Taipei Medical University Shuang Ho Hospital
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03958708

FIRST POSTED:
Wed, 22 May 2019 12:00:00 EDT

LAST UPDATE POSTED:
05/22/19 07:42AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03958708?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F08%2F2019&lupd_d=14&sort=nwst

Safety and Efficacy of THN102 in Patients With Parkinson’s Disease and Excessive Daytime Sleepiness

https://clinicaltrials.gov/ct2/show/NCT03624920?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F07%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Safety and Efficacy of THN102 in Patients With Parkinson’s Disease and Excessive Daytime Sleepiness

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: THN102 Dosage A;   Drug: THN102 Dosage B;   Drug: THN102 Dosage C
Sponsor:   Theranexus
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03624920

FIRST POSTED:
Fri, 10 Aug 2018 12:00:00 EDT

LAST UPDATE POSTED:
05/21/19 06:55AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03624920?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F07%2F2019&lupd_d=14&sort=nwst

VY-AADC02 for Parkinson’s Disease With Motor Fluctuations

https://clinicaltrials.gov/ct2/show/NCT03562494?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F06%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
VY-AADC02 for Parkinson’s Disease With Motor Fluctuations

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Biological: VY-AADC02;   Other: Placebo
Sponsors:   Neurocrine Biosciences;   Voyager Therapeutics
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03562494

FIRST POSTED:
Tue, 19 Jun 2018 12:00:00 EDT

LAST UPDATE POSTED:
05/20/19 07:34AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03562494?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F06%2F2019&lupd_d=14&sort=nwst

A Phase 1 Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects

https://clinicaltrials.gov/ct2/show/NCT03954600?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F03%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Phase 1 Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects

DESCRIPTION:
Condition:   Healthy Volunteers
Interventions:   Drug: NPT520-34 (125 mg);   Drug: Placebos (125 mg)
Sponsors:   Neuropore Therapies Inc.;   Celerion
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03954600

FIRST POSTED:
Fri, 17 May 2019 12:00:00 EDT

LAST UPDATE POSTED:
05/17/19 07:09AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03954600?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F03%2F2019&lupd_d=14&sort=nwst

A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson’s Disease Patients With Motor Fluctuations

https://clinicaltrials.gov/ct2/show/NCT03670953?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F02%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson’s Disease Patients With Motor Fluctuations

DESCRIPTION:
Condition:   Parkinson’s Disease (Disorder)
Interventions:   Drug: IR CD-LD;   Drug: IPX203 ER CD-LD;   Other: IPX203 placebo;   Other: IR CD-LD placebo
Sponsor:   IMPAX Laboratories, Inc.
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03670953

FIRST POSTED:
Fri, 14 Sep 2018 12:00:00 EDT

LAST UPDATE POSTED:
05/16/19 07:19AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03670953?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F02%2F2019&lupd_d=14&sort=nwst

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03716570?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F01%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson’s Disease
Interventions:   Drug: BIIB054;   Drug: Placebo
Sponsor:   Biogen
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03716570

FIRST POSTED:
Tue, 23 Oct 2018 12:00:00 EDT

LAST UPDATE POSTED:
05/15/19 07:32AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03716570?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F01%2F2019&lupd_d=14&sort=nwst

Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5HT2A Inverse Agonist, to Treat Impulse Control Disorders in Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03947216?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=04%2F29%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5HT2A Inverse Agonist, to Treat Impulse Control Disorders in Parkinson’s Disease.

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: Active drug: pimavanserin 17mg (2 strength tablets);   Drug: Placebo: 2 tablets containing same excipients except active compound;   Behavioral: Assessment of severity of ICD (impulse control disorders);   Behavioral: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors;   Behavioral: Assessment of quality of life;   Behavioral: Assessment of depression;   Behavioral: Assessment of cognition;   Behavioral: Assessment of severity of Parkinson Disease;   Procedure: Blood analysis;   Procedure: Cardiac monitoring
Sponsor:   University Hospital, Strasbourg, France
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03947216

FIRST POSTED:
Mon, 13 May 2019 12:00:00 EDT

LAST UPDATE POSTED:
05/13/19 07:43AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03947216?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=04%2F29%2F2019&lupd_d=14&sort=nwst

Single Ascending Dose Study of MEDI1341 in Healthy Volunteers

https://clinicaltrials.gov/ct2/show/NCT03272165?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=04%2F29%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Single Ascending Dose Study of MEDI1341 in Healthy Volunteers

DESCRIPTION:
Condition:   Parkinson’s Disease
Interventions:   Drug: MEDI1341;   Drug: Placebo
Sponsors:   AstraZeneca;   Covance;   MMS Holdings, Inc;   Catalent
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03272165

FIRST POSTED:
Tue, 05 Sep 2017 12:00:00 EDT

LAST UPDATE POSTED:
05/13/19 07:43AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03272165?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=04%2F29%2F2019&lupd_d=14&sort=nwst